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Background and Purpose—Fabry disease is an X-linked monogenic disorder caused by mutations in the GLA gene. Recent
data suggest that stroke in young adults may be associated with Fabry disease. We aimed to ascertain the prevalence
of this disorder among young adult patients with stroke in Portugal by GLA genotyping.
Methods—During 1 year, all patients aged 18 to 55 years with first-ever stroke, who were admitted into any of 12
neurology hospital departments in Portugal, were prospectively enrolled (n625). Ischemic stroke was classified
according to Trial of Org 10172 in Acute Stroke Treatment criteria. Alpha-galactosidase activity was further assayed
in all patients with GLA mutations.
Results—Four hundred ninety-three patients (mean age, 45.4 years; 61% male) underwent genetic analyses: 364 with ischemic
stroke, 89 with intracerebral hemorrhage, 26 with subarachnoid hemorrhage, and 14 with cerebral venous thrombosis. Twelve
patients had missense GLA mutations: 9 with ischemic stroke (p.R118C: n4; p.D313Y: n5), including 5 patients with an
identified cause of stroke (cardiac embolism: n2; small vessel disease: n2; other cause: n1), 2 with intracerebral
hemorrhage (p.R118C: n1; p.D313Y: n1), and one with cerebral venous thrombosis (p.R118C: n1). Leukocyte
-galactosidase activity was subnormal in the hemizygous males and subnormal or low-normal in the heterozygous females.
Estimated prevalence of missense GLA mutations was 2.4% (95% CI, 1.3% to 4.1%).
Conclusions—Despite a low diagnostic yield, screening for GLA mutations should probably be considered in different
types of stroke. Restricting investigation to patients with cryptogenic stroke may underestimate the true prevalence of
Fabry disease in young patients with stroke. (Stroke. 2010;41:431-436.)
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Stroke in young adults is an important cause of morbidityand mortality worldwide.1,2 In Portugal (population ap-
proximately 10 million), it is estimated that up to 3000 new
cases occur every year in the population aged 18 to 55 years.3
Despite extensive investigation, the cause of stroke in young
adults remains to be determined in up to 25% to 50% of
cases.1,2
Fabry disease (FD) is a rare X-linked lysosomal storage
disorder associated with increased risk of stroke in young
adults.4–7 The classical phenotype presents with early derma-
tologic, ophthalmologic, and peripheral nervous system in-
volvement. Renal, cardiac, and cerebrovascular complica-
tions are major causes of morbidity and mortality in adults.
Late-onset atypical phenotypes have also been reported.4
Because its clinical recognition requires a high index of
suspicion, the diagnosis of FD is often delayed or missed.5
Early diagnosis became particularly important because en-
zyme replacement therapy may prevent the late renal and
cardiac complications6,7 and seems to have a beneficial effect
on abnormal cerebral blood flow.8,9
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The underlying metabolic defect in FD is a deficiency of
lysosomal -galactosidase (Gal) due to mutations in the
Gal gene locus (GLA) located at Xq22.4,10 Deficient Gal
activity ultimately leads to widespread intracellular accumu-
lation of globotriaosylceramide and related neutral glyco-
sphingolipids, including in vascular endothelial and smooth
muscle cells.4,7 Mutations have been described throughout all
7 GLA exons and most families have private mutations.4,10
Typical for X-linked disorders, FD has a more variable and
usually milder and later phenotypic expression in females.4–7
A recent prospective study of cryptogenic stroke in young
adults (n721), using an Gal enzyme assay for screening,
suggested that up to 1.2% of patients with stroke 55 years
of age might have FD.11 However, the GLA mutations
identified in these cases were never reported. Moreover, in a
smaller retrospective study of similar patients (n103), no
GLA mutations were found in any of the subjects who had
low enzyme activity.12 The PORTuguese Young STROKE
Patients (PORTYSTROKE) study was designed to screen for
genetic disorders in young patients with stroke. We report the
results of GLA mutational analysis as the screening approach
to FD.
Methods
The PORTYSTROKE clinical protocol and the data collection and
storage procedures were approved respectively by the ethics com-
mittee of each participating hospital and by the Portuguese authority
for data protection. A computer database for online data entry was
specifically developed and monitored by an independent clinical
research organization. Individual patient records included demo-
graphic data, history of vascular risk factors, medical history, family
history emphasizing the classical features of FD, and the clinical and
brain imaging (CT or MRI) characteristics of stroke. Ischemic stroke
(IS) was classified according to the Trial of Org 10172 in Acute
Stroke Treatment (TOAST) criteria.13 The molecular genetics labo-
ratory was blinded as to the clinical and imaging data of each patient.
Patients
From November 1, 2006, through October 31, 2007, all patients aged
18 to 55 years presenting with first-ever stroke, admitted to neurol-
ogy departments in any of 12 major Portuguese hospitals, were
eligible for this study. Patient enrollment for genotyping required
written informed consent.
Laboratory Methods
Venous blood samples for molecular genetic analyses were collected
in tubes containing 5% edetate and mailed to the laboratory at room
temperature. Genomic DNA (gDNA) samples were extracted from 1
mL of blood with the Citogene Blood Kit (Citomed, Lisbon,
Portugal) and banked at 4°C. Leukocyte pellets were prepared from
5 mL of blood and frozen at 80°C until used for RNA extraction.
Total cellular RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany).
Two partially overlapping cDNA fragments, together comprising
1371 nucleotides of the 1418-nucleotide sequence of GLA messenger
RNA, were amplified from the RNA samples by reverse transcrip-
tion–polymerase chain reaction (PCR). The cDNA reverse
transcription-PCR amplicons contained a common sequence in their
respective 3 and 5 terminals, corresponding to part of exon 4. When
the cDNA could not be obtained, all 7 GLA exons and respective
exon/intron boundaries were PCR-amplified from the gDNA sam-
ples. The reverse transcription-PCR and PCR products were purified
and automatically sequenced in forward and reverse directions.
Details of these laboratory methods have been formerly published.14
The reference GLA gDNA and cDNA nucleotide sequences, respec-
tively GenBank Version X14448.1 and RefSeq Version NM_000169.2,
were obtained from the National Center for Biotechnology Information
(Bethesda, Md; www.ncbi.nlm.nih.gov/entrez/). Mutations detected in
the original GLA cDNA or gDNA analyses were confirmed in a
duplicate PCR amplification of the corresponding exon using the stored
gDNA samples.
A second blood sample for Gal enzyme assays was obtained
from all patients in whom a GLA mutation was identified. Plasma
and leukocyte activities of Gal were measured using a standard
fluorometric method.15 Normal range values for Gal enzyme
activity were 6 to 19 nmol/h/mL in plasma and 36 to 80 nmol/h/mg
in leukocytes.
In carriers of missense GLA mutations that were associated with
subnormal enzyme activity, multiplex ligation-dependent probe am-
plification (SALSA MLPA kit P159 GLA; MRC-Holland, Amster-
dam, The Netherlands) was additionally used to rule out the presence
of coexisting gross gene deletions and/or duplications that might
have been missed by gDNA or cDNA sequencing.
Control Population and Screening
To estimate the frequency in the general population of the missense
GLA mutations found in the stroke patient cohort, we used banked
gDNA samples of 130 (50 males) undergraduate medical students
aged 20 to 25 years, of 40 fertile males, aged 25 to 35 years, and of
130 (95 males) volunteer bone marrow donors, aged 25 to 45 years.
These control subjects were screened for the relevant GLA mutations
(see “Results”) by restriction enzyme analysis. To this end, endo-
nucleases HinfI and Hpy188III were selected with the NEBcutter
software (http://tools.neb.com/NEBcutter2/), respectively to identify
alleles p.R118C and p.D313Y. GLA exons 2 and 6 were PCR-
amplified as described14 and the digestion of the corresponding
amplicons was carried out according to the instructions of the
enzyme manufacturer (New England BioLabs, Hitchin, UK). In the
restriction analyses, gDNA samples of p.R118C or p.D313Y het-
erozygous carriers from the patient cohort were used as positive
controls.
Statistical Analyses
Parametric and nonparametric statistical analyses, as appropriate,
were performed with the SPSS software, Version 15.0. The preva-
lence of GLA gene mutations among patients and the corresponding
allele frequencies among healthy control subjects were estimated
using 95% CIs.16 Demographic and clinical data were summarized
using descriptive statistics. Comparisons of risk factors, personal
background, and family history were done according to demographic
characteristics (sex and age) and the presence or absence of GLA
gene mutations. The relative prevalence of GLA mutations was
compared for patients with or without evidence of small vessel
disease (lacunar stroke or leukoencephalopathy) and according to the
presence or absence of hypertension. The hypothesis that stroke in
the posterior circulation might have been relatively more frequent in
patients with missense GLA mutations7,17 was also specifically
addressed. A significance level of 0.05 was assumed for all
statistical tests.
Results
During the enrollment period, a total of 625 patients were
eligible for inclusion. Of these, 15 refused consent, 21 died
before inclusion, and 96 were lost for other reasons. There-
fore, the study cohort comprised 493 patients (61% males)
with a mean age of 45.4 years. The Table summarizes
demographic and clinical features of the enrolled patients. IS
occurred in 364 patients, intracerebral hemorrhage in 89,
subarachnoid hemorrhage in 26, and cerebral venous throm-
bosis (CVT) in 14.
Screening for GLA mutations was based on cDNA se-
quence analysis in 68% of the cases. As detailed in the Figure,
we identified one noncoding (g.1136CT in the 5-
untranslated region of exon 1) and 2 missense GLA mutations
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(p.R118C in exon 2, p.D313Y, in exon 6) in 10 patients with
IS (p.R118C: n4, 2 males; p.D313Y: n5, 3 males;
g.1136CT: n1, male), in 2 males with intracerebral
hemorrhage (p.R118C: n1; p.D313Y: n1), and in 2
females with CVT (p.R118C: n1; g.1136CT: n1). The
gDNA nucleotide changes corresponding to mutations
p.R118C and p.D313Y were, respectively, g.5251CT and
g.10645GT. MLPA analysis did not show gross gene
deletions or duplications in any of these patients.
Because leukocyte Gal activity was normal or above
normal in patients with mutation g.1136CT, their carriers
were not included in prevalence estimates. Leukocyte Gal
activity was subnormal in males and subnormal to low
normal in females with p.R118C and p.D313Y mutations.
The allelic frequencies of both the p.R118C and the p.D313Y
mutations were 0.0087 (6 of 686; 95% CI: 0.0035 to 0.0194)
and did not differ significantly between genders; none of
these mutations was identified in more than 400 X chromo-
somes of healthy control subjects (95% CI: 0.0000 to 0.0111).
The combined prevalence of GLA missense mutations in
the patient cohort was 2.4% (12 of 493; 95% CI: 1.4% to
4.3%) and showed no significant gender difference (2.3% in
males versus 2.6% in females). The prevalence of each
mutation was similar among the patients (1.2%) and did not
differ significantly between genders. The combined preva-
lence of GLA missense mutations among patients with IS was
2.5% (9 of 364; 95% CI: 1.2% to 4.7%). The combined
prevalence of GLA missense mutations among patients with
cryptogenic IS was 3.9% (4 of 104; 95% CI: 1.2% to 9.8%),
which did not significantly differ in comparison to patients
with an identified cause of stroke.
None of the patients carrying identical GLA mutations
were of the same family. The type and median number of
vascular risk factors, the characteristics of the stroke event,
and the prevalence of classic features of FD in the medical
history or family history did not significantly differ between
patients with GLA mutation and those without.
Among patients with IS or intracerebral hemorrhage, the
frequency of stroke in the posterior circulation was signifi-
cantly higher in those carrying missense GLA mutations
(Fisher exact test, P0.02). This was particularly evident in
patients with mutation p.R118C, of whom 80% (4 of 5) had
a stroke event in the territory of posterior circulation.
In patients presenting with IS and brain imaging evidence of
small vessel disease (lacunar stroke or leukoencephalopathy),
the overall prevalence of missense GLA mutations was 4.6% (6
of 132; 95% CI: 1.9% to 9.8%), increasing to 7.0% (4 of 57;
95% CI: 2.3% to 17.2%) in patients without hypertension and to
12.5% (3 of 24; 95% CI: 3.5% to 31.8%) in normotensive
patients with stroke in the posterior circulation.
Discussion
To our knowledge, this was the first study in which FD was
prospectively screened in a large cohort of unselected young
patients with stroke. We reasoned that not limiting eligibility
to cryptogenic stroke might decrease selection bias and would
be more appropriate to identify possible interactions between
GLA mutations and environmental risk factors, particularly
for populations with a very high prevalence of stroke, like the
Portuguese. This was also the first time that mutational
analysis was used to screen for FD in a large cohort with the
same sensitivity for both genders, overcoming the limitations
of Gal activity assays to diagnose FD in females.5 Exon
deletions and duplications as well as point mutations involv-
ing the last 16 amino acids of the Gal protein might have
been missed with our genotyping strategy. However, the
gross defects are rare and have been described in patients with
classic FD rather than in association with atypical pheno-
types, and no pathogenic GLA point mutations have been
reported in the last 15 amino acids of the enzyme (Human
Table. Demographic and Clinical Characteristics of the
Patient Cohort
Total
GLA
R118C
GLA
D313Y
GLA
(Total)
Study sample
No. of patients 493 6 6 12
Male 300 (60.9) 3 (50.0) 4 (66.7) 7 (58.3)
Age, years 47.0 41.0 46.5 43.0
Risk factors
Hypertension 233 (47.3) 4 (66.7) 1 (16.7) 5 (41.7)
Diabetes 74 (15.0) 0 (…) 1 (16.7) 1 (8.3)
Cardiac disease 54 (11.0) 1 (16.7) 1 (16.7) 2 (16.7)
Hyperlipidemia 222 (45.0) 4 (66.7) 1 (16.7) 5 (41.7)
Smoking 181 (36.7) 3 (50) 1 (16.7) 4 (33.3)
Alcohol 238 (48.3) 4 (66.7) 3 (50.0) 7 (58.3)
Oral contraception 87 (45.1) 2 (66.6) 0 (…) 2 (40.0)
Hormonal replacement 1 (0.52) 0 (…) 0 (…) 0 (…)
Median no. 2.0 2.5 1.0 2.0
History
Cutaneous disease 25 (5.1) 1 (16.7) 0 (…) 1 (8.3)
Ophthalmologic disease 45 (9.1) 1 (16.7) 0 (…) 1 (8.3)
Renal disease 37 (7.5) 1 (16.7) 0 (…) 1 (8.3)
Neuropathic pain 7 (1.4) 0 (…) 0 (…) 0 (…)
Family history
Stroke 215 (43.6) 2 (33.3) 2 (33.3) 4 (33.3)
Cardiac disease 179 (36.3) 3 (50.0) 3 (50.0) 6 (50.0)
Renal disease 48 (9.7) 1 (16.7) 0 (…) 1 (8.3)
Stroke
Ischemic 364 (73.8) 4 (66.7) 5 (83.3) 9 (75.0)
Cardiac embolism 80 1 1 2
Large vessel disease 55 … … …
Small vessel disease 98 1 1 2
Other known cause 27 1 … 1
Unknown cause 104 1 3 4
Intracerebral hemorrhage 89 (18.1) 1 (16.7) 1 (16.7) 2 (16.7)
Subarachnoid hemorrhage 26 (5.3) 0 (…) 0 (…) 0 (…)
CVT 14 (2.8) 1 (16.7) 0 (…) 1 (8.3)
Leukoencephalopathy 76 (15.4) 1 (16.7) 2 (33.3) 3 (25.0)
Posterior circulation 101 (20.5) 4 (66.6) 2 (33.3) 6 (50.0)
Modified Rankin Scale 2 135 (27.4) 3 (50.0) 2 (33.3) 5 (41.7)
Numbers in parentheses are percentages.
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Gene Mutation Database, HGMD; www.hgmd.cf.ac.uk/ac/
gene.php?geneGLA, accessed October 1, 2009).
The prevalence of GLA missense mutations was 2.4% in
the overall cohort and 3.8% in the subset of patients with
cryptogenic stroke. These results are comparable to those of
previous screening programs of atypical FD among patients
with cryptogenic stroke11 or with idiopathic left ventricular
hypertrophy.18–21 Except for stroke in the posterior arterial
territory, which was more frequent among patients with GLA
mutations, there were no significant demographic and clinical
differences between patients with GLA mutations and those
without. Of note, reporting of personal or family history of
possible complications of FD was no different in the 2
groups. The finding of GLA mutations in patients with
intracerebral hemorrhage was not surprising, because these
are a recognized cerebrovascular complication of FD,22 but
CVT had never been reported in association with FD.
Although a single case does not allow to conclude that Gal
deficiency is a risk factor for CVT, various abnormalities in
cerebral blood flow and in the walls of intracranial vessel
have been identified that are not exclusive of arterial sys-
tem7,17 and might contribute to a higher risk of CVT. In the
large observational Fabry Registry database, the diagnosis of
FD was established at later ages in patients who had stroke
than in patients who did not.22 Moreover, most patients with
stroke had not experienced renal or cardiac events before their
first stroke. These data are in accordance with our own
findings and suggest that the classical features of the disease
may be absent or more subtle in these patients. Furthermore,
the finding of GLA missense mutations in several patients
who had a concurrent cause of stroke by TOAST criteria
(Figure 1) suggests that screening of FD among patients with
stroke should not be restricted to the cryptogenic cases.
Evidence of small vessel disease (lacunar stroke or leukoen-
cephalopathy) without hypertension in young patients with IS
should prompt the search for FD, particularly when the stroke
occurs in the posterior circulation.
None of our patients carried a GLA mutation unequivocally
associated with the classical FD phenotype, but the 2 mis-
sense mutations that were identified have been previously
reported in patients with FD and were not found in over 400
X chromosomes of healthy Portuguese control subjects.
Figure. Alpha-galactosidase leukocyte and plasma enzyme activities in patients with missense GLA gene mutations. The normal ranges
for leukocyte and plasma -galactosidase activities are shadowed at the background. The clinical and brain imaging features of the
stroke event and the relevant details of the history and of the family history of each patient are also summarized.
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However, given the 95% CI for their estimated prevalence in
the general population, we cannot formally exclude that
p.R118C and p.D313Y are low-frequency, missense single
nucleotide polymorphisms, as previously suggested for the
p.D313Y allele.23
Mutation p.R118C was identified in a single case among
37 104 males enrolled in an Italian newborn screening pro-
gram24 but was not present in over 400 X chromosomes from
normal control subjects.24 However, in contrast to our find-
ings, the neonate carrying this mutation had 5% residual
enzyme activity. Experimental data suggest that mutation
p.R118C behaves similarly to other known late-onset GLA
mutations.24 Mutation p.R118C has also been reported in a
Portuguese family presenting with a mild clinical phenotype,
including angiokeratomas in a young adult female25 who had
no histological evidence of globotriaosylceramide deposition
in the kidney. Furthermore, the predominant association with
stroke in the posterior circulation indirectly supports a patho-
genic role for this mutation in cerebrovascular disease.
Mutation p.D313Y was first described in a patient with the
classical FD phenotype,26 but its pathogenic role has been
subsequently challenged.23,27 Studies in transfected cells char-
acterized the D313Y enzyme as a pH-sensitive variant associ-
ated with pseudodeficiency of Gal activity in plasma.23 None-
theless, in recent screenings of FD among patients with
idiopathic left ventricular hypertrophy, mutation p.D313Y
was regarded as either pathogenic19,20 or nonpathogenic.21
Unfortunately, none of these studies provided histological
evidence confirming or excluding the diagnosis of Fabry
cardiomyopathy in such patients and the issue of whether
mutation p.D313Y is pathogenic still remains open.
In our cohort, males with either the p.R118C or the
p.D313Y mutation had comparable plasma Gal activities
(approximately 40% the normal mean) with average leuko-
cyte activity, respectively, of approximately 35% and approx-
imately 50% of the normal. Of note, plasma Gal expression
in several of these subjects was within the relatively high
range observed in Japanese patients with a cardiac variant of
FD.28 Although Gal expression was comparatively higher in
leukocytes, the difference in the relative levels of Gal
activity in the leukocyte and plasma assays that we observed
in p.D313Y hemizygous males was much lower than ex-
pected from available in vitro data.23 In contrast to previous
reports of classically affected patients with FD,23,27 none of
our patients carried an additional missense GLA mutation in
cis with mutation p.D313Y.
None of the clinical trials of enzyme replacement therapy
with recombinant Gal enrolled patients with substantial
residual enzyme activity and there is no conclusive evidence
that enzyme replacement therapy initiated in adulthood de-
creases the risk of stroke in patients with classic FD.7
Therefore, no recommendations regarding enzyme replace-
ment therapy for the patients identified in this study can be
issued at this time.
The pathogenic mechanisms of stroke in FD are uncertain.7
Our findings suggest that GLA mutations associated with
relatively high residual Gal activity may add to the risk of
stroke in young adults, possibly by contributing to the
underlying multifactorial pathogenesis rather than through a
classic Mendelian effect. Alternatively, it might be speculated
that a late-onset cerebrovascular variant of FD is associated
with relatively high levels of residual Gal activity. These
data need further confirmation in properly designed case–
control and family segregation studies.
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